NCT01850030已完成3 期
A Double-Blind, Double-Dummy, Randomized, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization (Lotus I)
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Abbott
- 入组人数
- 1,070
- 试验地点
- 39
- 主要终点
- Percentage of Participants Being Pregnant as Measured by the Presence of Fetal Heart Beats at 12 Weeks´Gestation Using Transvaginal Ultrasound
研究概览
简要总结
Female inability to conceive a child. The purpose of this randomized, two-arm and double blind, double dummy study is to demonstrate that the treatment of a daily dose of 3x10mg dydrogesterone orally is as effective and safe as the daily dose of 3x200 mg micronized progesterone capsules administered intravaginally for the luteal support in patients undergoing IVF. The treatment will start on the day of oocyte retrieval and continue until pregnancy is negative or until week 12 gestation.Patients will be followed after treatment until 30 days after delivery to record any safety and tolerability data of the patient and their newborn(s).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 41 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Premenopausal females, age > 18 years < 42 years
- •Non-smokers. For females who were past smokers, they must have stopped tobacco usage for at least 3 months prior baseline visit
- •Early follicular phase (Day 2-4) Follicle stimulating hormone (FSH) less than or equal to 15 IU/L and estradiol (E2)within normal limits
- •Luteinizing hormone (LH), prolactin (PRL), T (testosterone) and thyroid-stimulating hormone (TSH), within the normal limits for the clinical laboratory, or considered not clinically significant by the Investigator within 6 months prior to screening
- •Documented history of infertility (e.g., unable to conceive for at least one year or for 6 months for women ≥ 38 years of age or bilateral tubal occlusion or absence)
- •Normal transvaginal ultrasound at screening (or within 14 days of screening) without evidence of clinically significant abnormality consistent with finding adequate for Assisted Reproductive Technology (ART) with respect to uterus and adnexa (no hydrosalpinx or clinically relevant uterine fibroids)
- •Negative pregnancy test on the day of pituitary down regulation (prior to administration of gonadotropin releasing hormones (GnRH) agonist or GnRH antagonist)
- •Clinically indicated protocol for induction of IVF with a fresh embryo
- •Single or dual embryo transfer
- •BMI ≥ 18 and ≤ 30 kg/m2
排除标准
- •Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematologic/immunologic, head, ears, eyes, nose, throat (HEENT), dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurologic/psychiatric, allergy, recent major surgery (< 3 months), or other relevant diseases as revealed by history, physical examination and/or laboratory assessments which could limit participation in or completion of the study
- •Acute urogenital disease
- •Known allergic reactions to progesterone products
- •Known allergic reactions to peanuts and peanut oil
- •Intake of experimental drug or participation in any other clinical trial within 30 days prior to study start
- •Mental disability or any other lack of fitness, in the Investigator's opinion, to preclude subjects to participate in or to complete the study
- •Current or recent substance abuse, including alcohol and tobacco (Note: Patients who stopped tobacco usage at least 3 months prior to screening visit would be allowed)
- •History of chemotherapy or radiotherapy
- •Patients with more than 3 unsuccessful IVF attempts
- •Contraindication for pregnancy
- •Refusal or inability to comply with the requirements of the study protocol for any reason, including scheduled clinic visits and laboratory tests
- •History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages
研究组 & 干预措施
Dydrogesterone 30 mg
Experimental
干预措施: Dydrogesterone 30 mg (Drug)
Dydrogesterone 30 mg
Experimental
干预措施: Placebo progesterone (Drug)
Micronized Progesterone 600 mg
Experimental
干预措施: Micronized Progesterone 600 mg (Drug)
Micronized Progesterone 600 mg
Experimental
干预措施: Placebo dydrogesterone (Drug)
结局指标
主要结局
Percentage of Participants Being Pregnant as Measured by the Presence of Fetal Heart Beats at 12 Weeks´Gestation Using Transvaginal Ultrasound
时间窗: 12 weeks´ gestation (at visit 6)
Percentage of participants being pregnant as measured by the presence of fetal heart beats at 12 weeks´gestation using transvaginal ultrasound
次要结局
- Percentage of Participants Being Pregnant as Measured by the Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer(Day 14 after embryo transfer)
- Percentage of Participants With a Successful Completion of Pregnancy(After delivery (about 9 months after IVF))
- Gender of the Newborn(After delivery (about 9 months after IVF))
研究者
研究点 (39)
Loading locations...
相似试验
已完成
不适用
A Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Two Proprietary Herbal Medicines as Mono Therapy and as Combination Therapy in Adult Subjects with Moderate to Severe Psoriasis.CTRI/2014/01/004277Dr JRKs Siddha Research and Pharmaceuticals Private Limited42
进行中（未招募）
不适用
Role of Qlin® (Natural cream spray) for external use in treating the patients with first to third degree haemorrhoidsCTRI/2017/03/008019Dobra Dela doo24
进行中（未招募）
1 期
A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 14.1Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865EUCTR2012-002215-26-ESAbbott Laboratories GmbH1,066
进行中（未招募）
1 期
A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 15.1Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865EUCTR2012-002215-26-BEAbbott Laboratories GmbH1,066
进行中（未招募）
1 期
A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 19.0Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865EUCTR2012-002215-26-ATAbbott Laboratories GmbH1,066